Drugs / BMS-986527
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07848295 | Dec 2026 → Oct 2030 expected | clear cell renal carcinoma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07848295 ↗ |